ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

A **first-in-class, once-weekly** infusion

FACTOR UP WITH ALTUVIIIO™

Higher-for-longer factor levels in the near-normal to normal range **(over 40%)** for most of the week

SWITCH IT UP

Factor VIII levels at 42%, 4 days after infusion

Hypothetical patient and scenario

INDICATION

ALTUVIIIO™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

Your healthcare provider may give you ALTUVIIIO when you have surgery.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?

Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center.

Please see full Prescribing Information.

In hemophilia A, Factor VIII is either missing or not working properly

When an injury causes a bleed, a process called hemostasis occurs at the injury site to form a clot and stop the bleed

Hemostasis is achieved in 2 parts:

- **Primary hemostasis:** Platelets are recruited to the site of the injury and, with the help of von Willebrand Factor (vWF), create a "platelet plug" to reduce blood loss
- **Secondary hemostasis:** This is where the multistep clotting cascade is activated to generate thrombin, which converts to fibrin and forms a mesh around the platelets to stabilize the clot

Without enough Factor VIII, your body's ability to generate thrombin is reduced, meaning:

Blood cannot clot properly



Excessive bleeding can occur

Restoring hemostasis is essential for stable clot formation

What are factor activity levels?

The amount of Factor VIII in your blood is called your "factor activity level"

Everyone's factor activity levels are different. People with lower factor levels have greater bleed risk, and people with higher factor activity levels have better protection. Every person has unique treatment goals. That's why it's important to talk to your doctor about managing your hemophilia.

General guidelines on Factor VIII levels and their impact on the ability to perform activities

Factor VIII Levels	Impact on Physical Activity/Lifestyle
Normal levels 50%-150% factor activity	 May engage in higher-impact activity without pain (sports, physical jobs, and active days)
Near-normal* ≥40%-<50% factor activity	Near-normal factor activity levels are currently undefined by the World Federation of Hemophilia
Mild hemophilia 5%-<40% factor activity	 May engage in higher risk activities (aerobics, pilates, bicycling, swimming), with some pain • Appropriate level of physical activity should be evaluated on a case-by-case basis • Supplemental factor is needed for surgery
Moderate hemophilia 1%-5% factor activity	 May engage in limited activity with some pain (walking, golfing, sailing, gardening), with a risk of spontaneous bleeds or microbleeds • Requires minor adjustments in lifestyle and the physical activity level can be mild and moderate • Supplemental factor is needed for surgery
Severe hemophilia <1% factor activity	 A person's lifestyle is considered "vulnerable," which means their level of physical activity is low to sedentary • There is a high risk of spontaneous bleeds and pain with target joints • Supplemental factor is needed for surgery

*WFH guidelines define the upper limit of mild hemophilia as 40% factor activity and the WFH *Introduction to Hemophilia* defines the normal range as 50% to 150%, which indicates that 40% to 50% would be in between mild hemophilia and normal, here referred to as "near-normal" levels.

People with hemophilia take prophylaxis treatments, or preventative treatments, to help keep their factor levels higher

For people treating on-demand, treatment increases their factor levels and restores hemostasis after a bleed occurs.

The more factor you have in your body, the better your bleed protection is, **which is why many people with hemophilia choose to treat with prophylaxis.**

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I need to know about ALTUVIIIO? (cont'd)

You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.

ALTUVIIIO™
Antihemophilic Factor (Recombinant),
Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

ALTUVIIIO is a once-weekly, first-in-class, Factor VIII replacement therapy
that keeps levels in the near-normal to normal range **(over 40%)** for most of the week, and stays above 18%* on average in adults — with 1 weekly infusion.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

*Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.

IMPORTANT SAFETY INFORMATION (CONT'D)

Who should not use ALTUVIIIO?

You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

ALTUVIIIO is a once-weekly, first-in-class, Factor VIII replacement therapy

WEEKLY
1x

The only once-weekly prophylaxis factor infusion

3-4x

Longer half-life, in a separate study with EHL and SHL therapies*

*This is information from a study in 13 previously treated adults with severe hemophilia A, that had the goal of comparing how long ALTUVIIIO, Adynovate® [Antihemophilic Factor (Recombinant), PEGylated], and Advate® [Antihemophilic Factor (Recombinant)] stayed in the body after 1 dose.

EHL=extended half-life; SHL=standard half-life.

IMPORTANT SAFETY INFORMATION (CONT'D)

What should I tell my healthcare provider before using ALTUVIIIO?

Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

In a Phase 1 study, ALTUVIIIO had a 3-4x longer half-life than EHL and SHL therapies*



*This is information from a study in 13 previously treated adults with severe hemophilia A, that had the goal of comparing how long ALTUVIIIO, Adynovate® [Antihemophilic Factor (Recombinant), PEGylated], and Advate® [Antihemophilic Factor (Recombinant)] stayed in the body after 1 dose. Half-life was 43 hours for ALTUVIIIO, 15 hours for Adynovate, and 11 hours for Advate.
Adynovate and Advate are registered trademarks of Baxalta Incorporated, a Takeda company.

In the XTEND-1 study, average Factor VIII levels

- Stayed above 40% for most of the week (near-normal to normal range)
- Stayed above 18%, on average, in adults for the entire week
  - Average trough levels were 9% for adolescents aged 12 years to under 18 years

In the XTEND-Kids study, average trough levels

- Were 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO?

You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Please see full Prescribing Information.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

ALTUVIIIO is engineered to last longer

Factor VIII levels at 43%, 4 days after infusion

Hypothetical patient and scenario

The unique design of ALTUVIIIO keeps factor levels higher for longer

ALTUVIIIO uniquely combines 3 components to help it stay in your body longer



Fc Fusion
helps Factor VIII recirculate in your blood

XTEN® Technology
shields Factor VIII from breaking down too early

vWF Fragments
keep Factor VIII in your blood for longer

vWF=von Willebrand Factor.

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO? (cont'd)

Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO? (cont'd)

The common side effects of ALTUVIIIO are headache, joint pain, and back pain.

These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

How was ALTUVIIIO studied?

Factor VIII levels at 42%, 4 days after infusion

Hypothetical patient and scenario

ALTUVIIIO WAS STUDIED IN XTEND-1

159 = **133** + **26**

Adults and Adolescents

158 males and 1 female with severe hemophilia (aged 12 years and older)

People in Group 1

switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.

Included 1 female participant

People in Group 2

switched from prior on-demand therapy to ALTUVIIIO on-demand for 26 weeks, and then to ALTUVIIIO prophylaxis for another 26 weeks

1 YEAR: total length of study →

Finding people's annualized bleed rate was the primary goal of the study

Children under 12 years were enrolled in XTEND-Kids, a pediatric study. XTEND-Kids enrolled 67 male previously treated patients <12 years of age with severe hemophilia A. Of the 67 enrolled subjects, all received at least 1 dose of ALTUVIIIO. Efficacy of prophylaxis was evaluated in 23 of these patients.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?

Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION (CONT'D)

Who should not use ALTUVIIIO?

You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.

ALTUVIIIO™
Antihemophilic Factor (Recombinant),
Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

Proven bleed protection with ALTUVIIIO prophylaxis

Factor VIII levels at 44%, 4 days after infusion

Hypothetical patient and scenario

DATA FROM THE XTEND-1 STUDY

0	0.7	0
Median bleeds per year* (median annualized bleed rate)	Mean bleeds per year* (mean annualized bleed rate) PRIMARY OUTCOME	Median joint bleeds per year* (median annualized joint bleed rate)

In the pediatric study, routine prophylaxis with ALTUVIIIO resulted in a mean ABR of 0.5* and a median ABR of 0.*

How were bleeds and joint bleeds measured in the trials?

- **Median ABR** was the middle number of all ABRs, when everyone's ABR was ordered from least to greatest
- **Mean ABR** was the average number based on everyone's ABR

Ask your doctor if switching to ALTUVIIIO is right for you

*Data based on treated bleeds.
ABR=annualized bleed rate.

IMPORTANT SAFETY INFORMATION (CONT'D)

What should I tell my healthcare provider before using ALTUVIIIO?

Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

Significant improvement in bleed protection with **ALTUVIIIO** prophylaxis

In Group 1:

133 people aged 12 years and older had prior prophylaxis therapy and switched to ALTUVIIIO. 78 of those people participated in a separate study to measure their ABRs on their prior prophylaxis. Comparing the results of the 78 people who participated in both studies showed:

ON AVERAGE...

People went from **3 bleeds** to **less than 1 bleed** a year (mean ABR 0.7)

That's a **77% reduction** in yearly bleeds (mean)*

AND

Over 52 weeks on ALTUVIIIO prophylaxis

64% of people had **zero** bleeds* vs 42% on prior prophylaxis

*Data based on treated bleeds.

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO?

You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

KNOW YOUR JOINTS ARE PROTECTED

Over 52 weeks on prophylaxis

72% of people had **zero** joint bleeds after switching to ALTUVIIIO*

A mean change of -1.5 (-2.7, -0.3) from starting point was observed in Hemophilia Joint Health Score (HJHS) total score.

HJHS is a validated tool used to measure joint health function. The study was designed so the investigators knew the patients were taking ALTUVIIIO which may have impacted their assessment of the patients' HJHS score.

100%
Target joint resolution

- Target joints are 3 or more spontaneous bleeds in a major joint in a consecutive 6-month period
- Target joints were considered resolved if 2 or fewer bleeds occurred in the target joint in 12 months

*Data based on treated bleeds.

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO? (cont'd)

Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

Demand
fewer yearly bleeds

In Group 2:

26 people aged 12 years and older were treated on-demand with ALTUVIIIO, then switched to ALTUVIIIO prophylaxis for 26 weeks

ON AVERAGE...

People who switched from ALTUVIIIO on-demand to ALTUVIIIO prophylaxis went from **21 bleeds** to **less than 1 bleed** a year (mean ABR 0.7)

That's a **97% reduction** in yearly bleeds (mean)*

AND

Over 26 weeks on ALTUVIIIO prophylaxis

77% of people had **zero** bleeds*

81% of people had **zero** joint bleeds*

*Data based on treated bleeds.

Switch it up from on-demand to prophylaxis with ALTUVIIIO

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO? (cont'd)

The common side effects of ALTUVIIIO are headache, joint pain, and back pain.

These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

Pain and physical health outcomes

Factor VIII levels at 42%, 4 days after infusion

Hypothetical patient and scenario

In people on once-weekly ALTUVIIIO who switched from prior prophylaxis in XTEND-1

PAIN AND PHYSICAL HEALTH SCORES FROM PATIENT REPORTED OUTCOMES*

Physical health

Change observed in Haem-A-QoL Physical Health Score from 37.0 at baseline to 29.7 at Week 52*

Pain intensity

Reduction observed in PROMIS Pain Intensity 3a Score from 2.5 at baseline to 2.2 at Week 52*

A lower score represents an overall improvement in these measures.

The XTEND-1 study was designed so patients and their doctors knew they were taking ALTUVIIIO which may have impacted these findings. The study was a single-arm study so all participants in the trial were treated with ALTUVIIIO and there was no other treatment to compare, which may impact the ability to assess the effect of ALTUVIIIO on these patient reported outcomes. The PROMIS tool was not specifically developed for use in hemophilia patients.

*Patient reported outcomes of pain intensity and physical health scores were evaluated in patients receiving ALTUVIIIO prophylaxis in Group 1. The PROMIS Pain intensity 3a instrument was used to assess pain, specifically the first question that rates the worst pain experienced during the last 7 days. Physical health scores were assessed in patients 17 years and older using the Physical Health Score of Haem-A-QoL, which evaluated factors such as painful swellings, presence of joint pain, pain with movement, difficulty walking far, and needing more time to get ready.

Haem-A-QoL=haemophilia quality of life questionnaire for adults; PROMIS=Patient-Reported Outcomes Measurement Information System.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?

Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.

Please see full Prescribing Information.

ALTUVIIIO™

Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

One infusion, a powerful* response

BLEED CONTROL WITH ALTUVIIIO

In the clinical trial, of 362 bleeds that occurred

97% were treated with 1 infusion†

*Based on the number of infusions needed to treat an active bleed.

†In the XTEND-1 study, 350 out of 362 bleeds that occurred were resolved with only one infusion.

IMPORTANT SAFETY INFORMATION (CONT'D)

Who should not use ALTUVIIIO?

You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.

Please see full Prescribing Information.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

In XTEND-1 and XTEND-Kids, people taking ALTUVIIIO had: **Zero** inhibitors **Zero** serious allergic reactions

Although no inhibitors were found, and no serious allergic reactions occurred in clinical studies, inhibitors and serious allergic reactions are possible with ALTUVIIIO.

In 159 people taking ALTUVIIIO in the XTEND-1 study:

21% of people had headache (33 people)

16% of people had joint pain (26 people)

6% of people had back pain (9 people)

In 67 children taking ALTUVIIIO in the XTEND-Kids study at the time of the interim analysis:

1% of children had headache (1 child)

IMPORTANT SAFETY INFORMATION (CONT'D)

What should I tell my healthcare provider before using ALTUVIIIO?

Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

One infusion. Once a week.

ALTUVIIIO offers the fewest weekly infusions among Factor VIII prophylaxis treatments



Watch a video on how to infuse ALTUVIIIO

*This is information from a study in 13 previously treated adults with severe hemophilia A, that had the goal of comparing how long ALTUVIIIO, Adynovate® [Antihemophilic Factor (Recombinant), PEGylated], and Advate® [Antihemophilic Factor (Recombinant)] stayed in the body after 1 dose. Half-life was 43 hours for ALTUVIIIO, 15 hours for Adynovate and 11 hours for Advate.

†Doses and dosing intervals may be adjusted.

Adynovate and Advate are registered trademarks of Baxalta Incorporated, a Takeda company.

One infusion to fit your needs. Factor Up with ALTUVIIIO prophylaxis.

Expect the same infusion process, whether weekly prophylaxis use, on-demand bleed control, or pre- or post-surgery management.

For information on the administration of ALTUVIIIO, including storage and handling, please refer to the Instructions For Use. Do not attempt to infuse by yourself unless you have been taught how by your healthcare provider or hemophilia treatment center.



IMPORTANT SAFETY INFORMATION

What are the possible side effects of ALTUVIIIO?

You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Please see full Prescribing Information.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Seamless support for your next step

No matter your situation, we are here with you every step of the way

We are committed to finding a way to help. Learn about all the resources and financial support available to eligible patients below.

Free Trial Plus Program

Get your first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription from your healthcare provider.

While you and your doctor are deciding what treatment is right for you, your dedicated Sanofi professional will review your health insurance information.

Enroll online and a dedicated Sanofi professional will contact you within 24 hours.*

Copay Program

Pay as little as $0 with maximum annual savings up to $20,000 with no income caps.

Get your Copay card by enrolling online or by contacting your dedicated Sanofi professional at 1-855-MyALTUVIIIO.*

Sign up now! >>

Factor Access Program

Access treatment even if your insurance is interrupted.

Enroll online and a dedicated Sanofi professional will contact you within 24 hours.

* Copay Program not valid for patients utilizing Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs to pay in part or in full for their prescriptions. Savings may vary depending on patients' out of pocket costs. Free Trial Plus valid only for a patient's first prescriptions and it is limited to one use per patient per product for their lifetime. Free products dispensed through the Free Trial Plus or Factor Access Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

TRICARE® is a registered trademark of the Department of Defense, Defense Health Agency (DHA).

Please see full Prescribing Information.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Connect >> with your CoRe today

Sanofi Hemophilia Community Relations and Education (CoRe) Managers provide information about ALTUVIIIO, living with hemophilia, and treatment options.

Questions?

Call 1-855-MyALTUVIIIO, Monday through Friday, 8 AM to 8 PM ET.

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of ALTUVIIIO? (cont'd)

Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

Please see full Prescribing Information.

Important Safety Information and Indication

INDICATION

ALTUVIIIO™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

Your healthcare provider may give you ALTUVIIIO when you have surgery.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?

Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.

Who should not use ALTUVIIIO?

You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.

What should I tell my healthcare provider before using ALTUVIIIO?

Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.

What are the possible side effects of ALTUVIIIO?

You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

The common side effects of ALTUVIIIO are headache, joint pain, and back pain.

These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.

Please see full Prescribing Information.

ALTUVIIIO™
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

FACTOR UP
with ALTUVIIIO

Higher factor levels for longer

Above 40% for most of the week (near-normal to normal range).*†

48

Hour half-life in adults

In a Phase 3 study,† ALTUVIIIO offered adults the longest half-life of any Factor VIII therapy.

0.7

Bleeds per year‡

Mean annual bleed rate observed in 128 people previously treated with prophylaxis therapy.†

In people taking ALTUVIIIO in the XTEND-1 study, 21% of people had headache, 16% had joint pain, and 6% had back pain

INDICATION

ALTUVIIIO™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

Your healthcare provider may give you ALTUVIIIO when you have surgery.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?

Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center.

Switch it up >>

and learn more!

*Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.

†159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.

‡Data based on treated bleeds.

sanofi

MAT-US-2210266-v3.0-07/2023

ALTUVIIIO™

Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl